Abstract
Abnormal activation of phosphoinositide 3-kinase (PI3K) signalling is very common in cancer, leading to deregulation of several intracellular processes normally controlled by this enzyme, including cell survival, growth, proliferation and migration. Mutations in the gene encoding the tumour suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which leads to uncontrolled activation of the PI3K pathway, are reported in different cancers. Among the downstream effectors of PI3Ks, 3- phosphoinositide-dependent protein kinase 1 (PDK1) and protein kinase B (PKB)/Akt have a key role in several cancer types. More recent data indicate that alteration of PDK1 is a critical component of oncogenic PI3K signalling in breast cancer, suggesting that inhibition of PDK1 can inhibit breast cancer progression. PDK1 has an essential role in regulating cell migration especially in the context of PTEN deficiency. Downregulation of PDK1 levels inhibits migration and experimental metastasis of human breast cancer cells. PDK1 activates a large number of proteins, including Akt, some PKC isoforms, S6K and SGK. Data also reveal that PDK1 is oncogenic and this is dependent on PI3K pathway. Therefore, accumulating evidence demonstrates that PDK1 is a valid therapeutic target and suggests that PDK1 inhibitors may be useful to prevent cancer progression and abnormal tissue dissemination. This review will focus on published data on the role of PDK1 in cancer and approaches used to inhibit PDK1.
Keywords: AGC kinase, cancer, metastasis, PDK1, PI3K, PTEN, phosphoinositide, suppressor phosphatase, homologue, chromosome 10 (PTEN)
Current Medicinal Chemistry
Title: Targeting PDK1 in Cancer
Volume: 18 Issue: 18
Author(s): C. Raimondi and M. Falasca
Affiliation:
Keywords: AGC kinase, cancer, metastasis, PDK1, PI3K, PTEN, phosphoinositide, suppressor phosphatase, homologue, chromosome 10 (PTEN)
Abstract: Abnormal activation of phosphoinositide 3-kinase (PI3K) signalling is very common in cancer, leading to deregulation of several intracellular processes normally controlled by this enzyme, including cell survival, growth, proliferation and migration. Mutations in the gene encoding the tumour suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which leads to uncontrolled activation of the PI3K pathway, are reported in different cancers. Among the downstream effectors of PI3Ks, 3- phosphoinositide-dependent protein kinase 1 (PDK1) and protein kinase B (PKB)/Akt have a key role in several cancer types. More recent data indicate that alteration of PDK1 is a critical component of oncogenic PI3K signalling in breast cancer, suggesting that inhibition of PDK1 can inhibit breast cancer progression. PDK1 has an essential role in regulating cell migration especially in the context of PTEN deficiency. Downregulation of PDK1 levels inhibits migration and experimental metastasis of human breast cancer cells. PDK1 activates a large number of proteins, including Akt, some PKC isoforms, S6K and SGK. Data also reveal that PDK1 is oncogenic and this is dependent on PI3K pathway. Therefore, accumulating evidence demonstrates that PDK1 is a valid therapeutic target and suggests that PDK1 inhibitors may be useful to prevent cancer progression and abnormal tissue dissemination. This review will focus on published data on the role of PDK1 in cancer and approaches used to inhibit PDK1.
Export Options
About this article
Cite this article as:
Raimondi C. and Falasca M., Targeting PDK1 in Cancer, Current Medicinal Chemistry 2011; 18 (18) . https://dx.doi.org/10.2174/092986711796011238
DOI https://dx.doi.org/10.2174/092986711796011238 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets The Emerging Diabetes Online Community
Current Diabetes Reviews Teaching Pharmacogenetics in Low and Middle Income Countries (LMICs): An Empirical Study of the Lessons Learned
Current Pharmacogenomics and Personalized Medicine Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers
Current Pharmaceutical Biotechnology CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Progress and Pitfalls in the Identification of Cancer Stem Cell-Targeting Therapies in Head and Neck Squamous Cell Carcinoma
Current Medicinal Chemistry An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews A Promising Anti-Cancer and Anti-Oxidant Agents Based on the Pyrrole and Fused Pyrrole: Synthesis, Docking Studies and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Computational & Statistical Methodologies to Identify Biomarkers in Cancer
Current Cancer Therapy Reviews Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Current Cancer Drug Targets Bladder Injury During Cesarean Delivery
Current Women`s Health Reviews